国际神经病学神经外科学杂志2025，Vol.52Issue(4)：61-69,9.DOI:10.16636/j.cnki.jinn.1673-2642.2025.04.010
双特异性抗体免疫疗法在胶质母细胞瘤治疗中的研究进展
Research advances in bispecific antibody immunotherapy in treatment of glioblastoma
王贺璐 1胡德豫 1李智健 1张洪涛2
作者信息
- 1. 山东第二医科大学临床医学院,山东 潍坊 261000
- 2. 烟台毓璜顶医院神经外科,山东 烟台 264000
- 折叠
摘要
Abstract
There are still significant challenges in the treatment of glioblastoma(GBM)due to the immunosuppressive microenvironment,the blood-brain barrier(BBB),and high heterogeneity,and there is a poor responses to conventional therapies such as immune checkpoint inhibitors(ICIs).Bispecific antibody(BsAb),which can simultaneously bridge T cells and tumor antigens(such as EGFRvⅢ,HER2,and B7-H3),have shown certain potential in overcoming the therapeutic challenges of GBM in preclinical studies.This article systematically reviews the research advances and mechanisms of action of BsAb,including bispecific T-cell engager(BiTE),in the treatment of GBM.Studies have shown that BsAb targeting the aforementioned antigens can effectively activate T cells,promote their tumor infiltration,and specifically kill GBM cells,thereby significantly improving survival rates in various preclinical models(such as orthotopic xenograft models and humanized models),and BiTE therapy has also shown promise in inducing durable antitumor effects.关键词
胶质母细胞瘤/免疫治疗/耐药性/免疫微环境/血脑屏障/免疫抑制剂/双特异性抗体Key words
glioblastoma/immunotherapy/drug resistance/tumor immune microenvironment/blood-brain barrier/immunosuppressant/bispecific antibody分类
医药卫生引用本文复制引用
王贺璐,胡德豫,李智健,张洪涛..双特异性抗体免疫疗法在胶质母细胞瘤治疗中的研究进展[J].国际神经病学神经外科学杂志,2025,52(4):61-69,9.
